Analyst Thomas Shrader of BTIG maintained a Buy rating on Inmune Bio (INMB – Research Report), retaining the price target of $21.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Thomas Shrader has given his Buy rating due to a combination of factors related to Inmune Bio’s strategic advancements and promising clinical developments. The company’s CORDStrom program for RDEB showed potential improvements in reducing itch, which is a significant quality of life factor for patients, although this program is not expected to be the main focus for future growth. The primary value driver for Inmune Bio is its XPro program for Alzheimer’s Disease (AD), with a Phase 2 trial (AD02) in progress and topline data anticipated in June 2025.
Inmune Bio has implemented a patient enrichment strategy and is using a novel clinical endpoint, EMACC, which recent data suggests is performing well. The trial is adequately powered due to the enrichment strategy and historical data comparisons. Moreover, the EMACC endpoint shows a correlation with the standard CDR-SB endpoint, potentially facilitating regulatory acceptance. These strategic and methodological approaches, along with ongoing developments, underpin Shrader’s positive outlook and Buy rating for the stock.
In another report released yesterday, Scotiabank also maintained a Buy rating on the stock with a $23.00 price target.